+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a fixed-dose combination strategy, known as the Polypill Approach for Multiple Cardiovascular Risk Factors PACIF, to manage hypertension, dyslipidemia, and type 2 diabetes in adults aged 50 to 75 years without prior cardiovascular disease in China. This multicenter randomized controlled trial aims to see if this polypill approach can improve 10-year cardiovascular disease risk and reduce major cardiovascular events and cognitive decline compared with usual care. Participants will be randomly assigned to receive either the fixed-dose combination strategy or usual care. The intervention includes eight fixed-dose formulations combining blood pressure-lowering, lipid-lowering, and glucose-lowering medications such as olmesartan medoxomilamlodipine, rosuvastatin, ezetimibe, dapagliflozin, and indapamide in selected formulations. Treatment is adjusted based on blood pressure, lipid, and glucose targets, with additional medications allowed if targets are not met. During the study, participants will be monitored over months to assess changes in cardiovascular risk factors, achievement of treatment goals, medication adherence, and cognitive outcomes such as dementia. The primary outcomes include estimated 10-year cardiovascular risk at 12 months and a composite of major cardiovascular events at 36 months. Safety and quality of life will also be evaluated throughout the trial lasting up to 36 months, with ongoing follow-up and assessments.

Age: 50Years - 75YearsAll GendersPhase Not Applicable
15 locations